Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
Drug makers in Japan are moving to curb shipments for the acute pancreatitis drug nafamostat as its demand from medical institutions is soaring on the back of reports that it might be effective against the novel coronavirus disease (COVID-19). University…
To read the full story
Related Article
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
- Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…